Candida auris Builds Multiple Genomes to Outsmart Antifungals

Genomic Multiplication: A New Survival Tactic

Researchers at the University of Exeter and City St George’s University in London have identified a novel strategy by which the dangerous yeast Candida auris evades treatment. In a study published this week, the team showed that the fungus can generate several copies of its entire genome, each containing mutations that help it survive drug exposure.

The discovery came after scientists examined clinical isolates from patients who had failed standard antifungal regimens. By sequencing the DNA, they found that the yeast had duplicated large sections of its genome and altered a key gene involved in cell wall maintenance. These changes reduce the effectiveness of commonly used medications such as echinocandins and azoles.

The researchers used high‑throughput sequencing to compare healthy and drug‑resistant strains. They observed that the resistant strains carried up to five copies of a chromosome that houses the ERG11 gene, which encodes an enzyme targeted by azole drugs. Each copy carried a subtle mutation that lowered drug binding. The result is a cumulative decrease in drug susceptibility.

How Does This Affect Treatment Options?

Dr. Sarah L. Davies, lead author, explained, „It’s like the yeast is creating backup plans. If one copy of the gene is blocked by the drug, the others can keep functioning.” The team also noted that the duplicated chromosomes were not static; they could be reshuffled during cell division, allowing the fungus to adapt quickly to new drug pressures.

This mechanism differs from the previously known resistance pathways, such as overexpression of efflux pumps or point mutations in target enzymes. Instead, Candida auris appears to use genomic plasticity as a rapid response system, enabling it to survive in hostile environments.

The findings raise concerns about the long‑term efficacy of current antifungal therapies. If the yeast can keep generating new genomic copies, it may develop resistance to multiple drug classes simultaneously. Hospitals worldwide have already reported outbreaks of multi‑drug‑resistant C. auris, leading to high mortality rates.

What Can Be Done to Counteract This Threat?

Dr. Michael Patel, an infectious disease specialist not involved in the study, cautioned, „This new mechanism means we might need combination therapies or drugs that target the genome duplication process itself.” He added that surveillance programs should monitor not only drug resistance mutations but also genomic copy number variations.

The study also suggests that diagnostic labs should incorporate genomic profiling into routine testing. Early detection of genome duplication could inform treatment choices and prevent treatment failures.

The research team is now exploring inhibitors that block the enzymes responsible for chromosome replication in fungi. Preliminary data show that a small‑molecule compound can reduce the number of duplicated chromosomes, restoring drug sensitivity in laboratory strains. If successful, such inhibitors could be paired with existing antifungals to enhance their potency.

Public health authorities are urged to update guidelines for managing C. auris infections. Enhanced infection control measures, rapid diagnostics, and stewardship of antifungal use are essential to curb the spread of this adaptable pathogen.

Frequently Asked Questions

Q1: How quickly can Candida auris develop this genomic duplication? A1: The duplication can occur within a few generations under drug pressure, allowing the yeast to rapidly acquire resistance.

Q2: Are current antifungal drugs still effective against these new strains? A2: Some strains remain susceptible to combination therapies, but many show reduced sensitivity, especially to azoles and echinocandins.

Q3: What steps should hospitals take to prevent outbreaks? A3: Implement strict hand hygiene, isolate infected patients, and use rapid genomic testing to detect resistant strains early.